Story Poster
Photo by Patrick O'Brien/Phenom
Basketball Recruiting

Top-50 incoming junior Jalen Rougier-Roane talks recruitment

July 21, 2023

In March, Sidwell Friends (DC) guard Jalen Rougier-Roane dislocated his knee cap and it took a turn at the end of his season. The 6-foot-5 guard returned to the court just in time this summer for the major live period events and hasn’t disappointed.

The dynamic guard was named to the All-MAC team after a successful season with Sidwell Friends and continued that success into his time with Team Takeover. 

Rougier-Roane is so highly-touted because he can play multiple positions, plays the game the right way on both ends, and hasn’t lost his scoring touch at all since returning to injury. It’s the reason why so many programs are in heavy pursuit of him, and continue to be in pursuit.

He talked with to discuss his recruitment and also gave tidbits on his game and development.

Which schools are heavily involved?

“Xavier, Providence, and Virginia Tech right now.”

Are any newer schools in the mix?

“Boston College recently.”

Xavier, what is the pitch and your relationship with Sean Miller?

“Xavier right now has seen my development and loves my game. I talked to Coach Miller on the 15th and he’s a great coach coming off a strong year.”

How about Providence and Kim English?

“Kim English has thought very highly of me since he was at George Mason. So, we have built a strong connection over time.”

How about Virginia Tech?

“Built a good relationship. They offered me last year. Great program and coach.”

Are you going to take any visits?

“Xavier's visit is being planned currently and Providence's as well.”

And how has your game evolved this year?

“I’ve gained a lot of confidence and my shooting has taken a massive jump as a shot-maker and a finisher.”

How would you like your game to evolve?

“I would like to create my own shot better and also be able to facilitate an offense.”

subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.